Article Data

  • Views 447
  • Dowloads 154

Editorials

Open Access

Difficulties and inequities in access to homologous recombination deficiency testing in ovarian cancer patients

  • Massimo Barberis1,*,

1Division of Experimental Oncology, European Institute of Oncology, IRCCS, 20139 Milano, Italy

DOI: 10.22514/ejgo.2024.042 Vol.45,Issue 3,June 2024 pp.1-3

Submitted: 12 December 2023 Accepted: 02 January 2024

Published: 15 June 2024

*Corresponding Author(s): Massimo Barberis E-mail: massimo.barberis@ieo.it

Keywords

Ovarian cancer; HRD; Inequity; Access


Cite and Share

Massimo Barberis. Difficulties and inequities in access to homologous recombination deficiency testing in ovarian cancer patients. European Journal of Gynaecological Oncology. 2024. 45(3);1-3.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] AIOM-AIRTUM. The numbers of cancer in Italy. 2023. Available at: https://www.aiom.it/wp-content/uploads/2023/12/2023_AIOM_NDC_def.pdf (Accessed: 14 December 2023).

[3] Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, et al. Cell origins of high-grade serous ovarian cancer. Cancers. 2018; 10: 433.

[4] Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. New England Journal of Medicine. 2019; 381: 2403–2415.

[5] González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381: 2391–2402.

[6] Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine. 2019; 381: 2416–2428.

[7] Swisher EM, Aghajanian C, O’Malley DM, Fleming GF, Kaufmann SH, Levine DA, et al. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology. 2022; 164: 245–253.

[8] LYNPARZAÒ. Highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf (Accessed: 8 May 2020).

[9] EMA Lynparza. Summary of opinion. Post authorization. 2017. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-35-ii-36_en.pdf (Accessed: 18 September 2020).

[10] AIFA Lynparza. Reimbursement approval. 2023. Available at: https://www.aifa.gov.it/documents/20142/961234/Determina_194-2022_Lynparza.pdf (Accessed: 18 March 2022).

[11] Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology. 2022; 33: 276–287.

[12] Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology. 2020; 31: 1606–1622.

[13] Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discovery. 2015; 5: 1137–1154.

[14] Weichert W, Lukashchuk N, Yarunin A, Riva L, Easter A, Bannister H, et al. An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer. International Journal of Gynecological Cancer. 2021; 31: A1–A395.

[15] Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, et al. Locally performed HRD testing for ovarian cancer? Yes, we can! Cancers. 2022; 15: 43.

[16] Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica. 2022; 114: 288–294.

[17] Kekeeva T, Andreeva Y, Tanas A, Kalinkin A, Khokhlova S, Tikhomirova T, et al. HRD testing of ovarian cancer in routine practice: what are we dealing with? International Journal of Molecular Sciences. 2023; 24: 10497.

[18] Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, et al. Access and quality of biomarker testing for precision oncology in Europe. European Journal of Cancer. 2022; 176: 70–77.

[19] ESGO Consortium of Accreditated Centers. Requirements for ESGO accreditation & re-accreditation of European Training Centres in Gynaecological Oncology. 2023. Available at: https://esgo.org/media/2023/04/Requirements-for-Accreditation-Training-Centres-2023.pdf (Accessed: 24 April 2023).

[20] European Cancer Patient Coalition. Realising the potential of genomic technologies in cancer care. 2021. Available at: https://ecpc.org/wp-content/uploads/2021/12/Report-Realising-the-potential-of-genomic-technologies-in-cancer-care-2021.pdf. (Accessed: 7 December 2021).

[21] European Commission, Directorate-General for Employment, Social Affairs and Inclusion, McGrath J. Analysis of shortage and surplus occupations 2020, Publications Office of the European Union. 2020. Available at: https://data.europa.eu/doi/10.2767/933528 (Accessed: 28 March 2023).


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top